Spectrum Pharma (SPPI) Misses Q3 EPS by 3c, Offers FY Guidace

Spectrum Pharma (NASDAQ: SPPI) reported Q3 EPS of ($0.28), $0.03 worse than the analyst estimate of ($0.25).

2015 Financial Guidance

Spectrum raises guidance on year-end cash to over $125 million, up from the Company’s previous guidance of $110 million excluding any new business development transactions.

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c